Invex Therapeutics Ltd (IXC.AX)
AUD 0.07
(0.0%)
AUD 0.07
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | -0.02 AUD | 78.2% |
| 2023 | -0.10 AUD | -90.11% |
| 2022 | -0.05 AUD | -73.03% |
| 2021 | -0.03 AUD | 49.16% |
| 2020 | -0.06 AUD | -510.2% |
| 2019 | -0.01 AUD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 FY | - AUD | 78.2% |
| 2024 Q2 | -0.03 AUD | 0.0% |
| 2024 Q4 | 0.01 AUD | 0.0% |
| 2023 Q3 | -0.03 AUD | 49.22% |
| 2023 FY | - AUD | -90.11% |
| 2023 Q4 | -0.05 AUD | -99.62% |
| 2023 Q2 | -0.05 AUD | -100.0% |
| 2023 Q1 | -0.03 AUD | 10.8% |
| 2022 Q2 | -0.02 AUD | -100.84% |
| 2022 Q1 | -0.01 AUD | 26.99% |
| 2022 FY | - AUD | -73.03% |
| 2022 Q4 | -0.03 AUD | -97.93% |
| 2022 Q3 | -0.01 AUD | 39.33% |
| 2021 FY | - AUD | 49.16% |
| 2021 Q1 | -0.01 AUD | 71.72% |
| 2021 Q4 | -0.02 AUD | -101.23% |
| 2021 Q3 | -0.01 AUD | 42.55% |
| 2021 Q2 | -0.01 AUD | -25.89% |
| 2020 FY | - AUD | -510.2% |
| 2020 Q4 | -0.04 AUD | -253.57% |
| 2020 Q3 | -0.01 AUD | 44.55% |
| 2020 Q2 | -0.02 AUD | -100.0% |
| 2020 Q1 | -0.01 AUD | 0.0% |
| 2019 Q3 | -0.00 AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |